中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2010年
22期
3048-3049
,共2页
肝炎,乙型,慢性%阿德福韦酯%胸腺肽α1
肝炎,乙型,慢性%阿德福韋酯%胸腺肽α1
간염,을형,만성%아덕복위지%흉선태α1
Hepatitis B,chronic%Adefovir%Thymopeptides α1
目的 探讨阿德福韦酯(ADV)与胸腺肽α1联合治疗慢性乙型肝炎(CHB)抗乙肝病毒(HBV)的疗效.方法 67例HBeAg阳性CHB患者分成联用组和单用组.联用组34例,联用ADV及胸腺肽α1治疗26周,随后继续单用ADV至52周.单用组33例,单用ADV治疗52周.定期检测丙氨酸氨基转氨酶(ALT)、总胆红素(TBil)、HBV DNA、HBeAg、抗-HBe,两组在治疗结束时进行疗效评价.结果 两组治疗后肝功能(ACT、TBil)均有明显改善,两组间差异无统计学意义(均P＞0.05),联用组HBeAg/抗-HBe血清转换率41.2%、HBV DNA阴转率67.6%均明显高于单用组(均P＜0.05).结论 ADV联用胸腺肽α1治疗HBeAg阳性CHB疗效优于单用ADV.显示ADV与胸腺肽α1联用能增强抗HBV的效力,有助于病毒的清除.
目的 探討阿德福韋酯(ADV)與胸腺肽α1聯閤治療慢性乙型肝炎(CHB)抗乙肝病毒(HBV)的療效.方法 67例HBeAg暘性CHB患者分成聯用組和單用組.聯用組34例,聯用ADV及胸腺肽α1治療26週,隨後繼續單用ADV至52週.單用組33例,單用ADV治療52週.定期檢測丙氨痠氨基轉氨酶(ALT)、總膽紅素(TBil)、HBV DNA、HBeAg、抗-HBe,兩組在治療結束時進行療效評價.結果 兩組治療後肝功能(ACT、TBil)均有明顯改善,兩組間差異無統計學意義(均P＞0.05),聯用組HBeAg/抗-HBe血清轉換率41.2%、HBV DNA陰轉率67.6%均明顯高于單用組(均P＜0.05).結論 ADV聯用胸腺肽α1治療HBeAg暘性CHB療效優于單用ADV.顯示ADV與胸腺肽α1聯用能增彊抗HBV的效力,有助于病毒的清除.
목적 탐토아덕복위지(ADV)여흉선태α1연합치료만성을형간염(CHB)항을간병독(HBV)적료효.방법 67례HBeAg양성CHB환자분성련용조화단용조.련용조34례,련용ADV급흉선태α1치료26주,수후계속단용ADV지52주.단용조33례,단용ADV치료52주.정기검측병안산안기전안매(ALT)、총담홍소(TBil)、HBV DNA、HBeAg、항-HBe,량조재치료결속시진행료효평개.결과 량조치료후간공능(ACT、TBil)균유명현개선,량조간차이무통계학의의(균P＞0.05),련용조HBeAg/항-HBe혈청전환솔41.2%、HBV DNA음전솔67.6%균명현고우단용조(균P＜0.05).결론 ADV련용흉선태α1치료HBeAg양성CHB료효우우단용ADV.현시ADV여흉선태α1련용능증강항HBV적효력,유조우병독적청제.
Objective To explore the effects of adefovir velocimeter(ADV) combined with Thymopeptides α1 in treatment of patients with chronic hepatitis B (CHB) against hepatitis B virus (HBV). Methods 67 cases of CHB of positive HBeAg were divided into coupling group and single group. 34 cases of coupling group, after being treated for 26 weeks with thymopeptides α1 and ADV,continued to be treated 52 weeks with ADV. 33 cases of single group were treated for 52 weeks with ADV alone. Alanine aminotransferase periodically (ALT), total bilirubin, HBV DNA,HBeAg,anti-HBe were detected at regular intervals. Efficacy were evaluated after finishing the treatment. Results The liver function were both improved obviously in two groups (P ＞ 0. 05). Frequencen of seroconversio of HBeAg/anti-HBe and negative conversion ratio of HBV DNA were much higher in coupling group than that in single group(P ＜ 0. 05). Conclusions The effects were better with Thymopeptides α1 and ADV than that with single ADV. Coupling Thymopeptides α1 and ADV could help to resist and remove HBV.
